evidencegaps
Primary study · included by 1 review

Serum autoantibody reactivity in bullous pemphigoid is associated with neuropsychiatric disorders and the use of antidiabetics and antipsychotics: a large, prospective cohort study.

Dikmen 2022 · Dikmen H O, Yilmaz K, Benoit S, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2022

Included by

Diagnostic Agreement in Subepidermal Blistering Diseases: Is ELISA Test Reliable as Direct Immunofluorescence? A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.
Non-Cochrane · DTA · 2026 · cited as Dikmen 2022 · Table 2; References
Outcome this study informsPooled effectEvidenceCertainty
Diagnostic agreement between ELISA and DIF (risk difference in test positivity)
ELISA (BP180 and/or BP230) in bullous pemphigoid (index test) vs Direct immunofluorescence (DIF, reference standard) · At first diagnosis, before immunosuppressive therapy
RD 0.19 [0.13, 0.25]27 studies · 2238 participantsGRADE not reported
Diagnostic agreement between ELISA and DIF (risk difference in test positivity)
ELISA for BP180 autoantibodies (index test) vs Direct immunofluorescence (DIF, reference standard) · At first diagnosis, before immunosuppressive therapy
RD 0.26 [0.19, 0.33]35 studies · 2776 participantsGRADE not reported
Diagnostic agreement between ELISA and DIF (risk difference in test positivity)
ELISA for BP230 autoantibodies (index test) vs Direct immunofluorescence (DIF, reference standard) · At first diagnosis, before immunosuppressive therapy
RD 0.59 [0.47, 0.71]27 studies · 2097 participantsGRADE not reported

1 including review in total.